High-throughput Fluorescent Protein Kinase Assays

Information

  • Research Project
  • 6549995
  • ApplicationId
    6549995
  • Core Project Number
    R43GM066439
  • Full Project Number
    1R43GM066439-01
  • Serial Number
    66439
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/20/2002 - 22 years ago
  • Project End Date
    3/19/2004 - 20 years ago
  • Program Officer Name
    JONES, WARREN
  • Budget Start Date
    9/20/2002 - 22 years ago
  • Budget End Date
    3/19/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/19/2002 - 22 years ago

High-throughput Fluorescent Protein Kinase Assays

DESCRIPTION (provided by applicant): Protein kinases catalyze the phosphorylation of serine (Ser), threonine (Thr), and tyrosine (Tyr) residues in peptides and proteins, and comprise the largest superfamily of enzymes in eukaryotes with an estimated 500 genes in the human genome. Because most intracellular processes are regulated by protein phosphorylation, dysregulation of protein kinases can lead to a variety of disease states. Protein kinases are therefore important targets for drug discovery and development. Protein kinase-targeted drug discovery requires the ability to rapidly screen compounds for their ability to specifically inhibit selected protein kinases. To facilitate the high-throughput screening of kinase activities we will develop microplate protein kinase assays using a proprietary fluorescence technology developed at the University of Utah. First, we will prepare two sets of fluorescently labeled synthetic peptides. One set will be used to assay protein Ser/Thr kinases, the other for protein Tyr kinases. Second, we will optimize each protein kinase assay system for use in standard 96-well and 384-well fluorescence microplate readers. Based on feedback from outside evaluators, we will optimize and develop commercial versions of these protein kinase assay kits to be sold to the research community and companies involved in drug discovery and development.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100110
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:100110\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ECHELON BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84108
  • Organization District
    UNITED STATES